Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases

Journal of Infection

Volumn 64, Issue 2, 2012, Pages 176-183

  Rodríguez Baño, Jesús ^a,b   Miró, Elisenda ^c   Villar, Macarena ^a   Coelho, Alicia ^d   Gozalo, Mónica ^e   Borrell, Nuria ^f   Bou, Germán ^g   Conejo, M Carmen ^b   Pomar, Virginia ^c   Aracil, Belén ^h   Larrosa, Nieves ^d   Agüero, Jesús ^e,i   Oliver, Antonio ^f   Fernández, Ana ^g   Oteo, Jesús ^h   Pascual, Alvaro ^a,b   Navarro, Ferran ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g HOSPITAL JUAN CANALEJO   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

ⁱ UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Lactamases; Bloodstream infections; Escherichia coli; Klebsiella pneumoniae; Plasmid mediated AmpC; Proteus mirabilis; Risk factors

Indexed keywords

AMIKACIN; BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATION; CLINICAL FEATURE; CONTROLLED STUDY; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; PROTEUS MIRABILIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PLASMIDS; PROTEUS MIRABILIS; SPAIN; YOUNG ADULT;

EID: 84855887832     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.11.016     Document Type: Article

References (25)

1. Pitout J.D., Laupland K.B. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
2. Jacoby G.A. AmpC β-lactamases. Clin Microbiol Rev 2009, 22:161-182.
3. Pai H., Kang C.I., Byeon J.H., Lee K.D., Park W.B., Kim H.B., et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-β-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2004, 48:3720-3728.
4. Yan J.J., Ko W.V., Wu J.J., Tsai S.H., Chuang C.L. Epidemiological investigation of bloodstream infections by extended spectrum cephalosporin-resistant Escherichia coli in a Taiwanese teaching hospital. J Clin Microbiol 2004, 42:3329-3332.
5. Pitout J.D., Gregson D.B., Church D.L., Laupland K.B. Population-based laboratory surveillance for AmpC β-lactamase-producing Escherichia coli. Calgary Emerg Infect Dis 2007, 13:443-448.
6. Sidjabat H.E., Paterson D.L., Qureshi Z.A., Adams-Haduch J.M., O'Keefe A., Pascual A., et al. Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli. Clin Infect Dis 2009, 48:739-744.
7. Park Y.S., Yoo S., Seo M.R., Kim J.Y., Cho Y.K., Pai H. Risk factors and clinicalfeatures of infections caused by plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents 2009, 34:38-43.
8. Lee C.H., Su L.H., Li C.C., Chien C.C., Tang Y.F., Liu J.W. Microbiologic and clinical implications of bacteremia due to extended-spectrum-β-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC β-lactamase DHA-1. Antimicrob Agents Chemother 2010, 54:5395-5398.
9. Courpon-Claudinon A., Lefort A., Panhard X., Clermont O., Dornic Q., Fantin B., et al. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clin Microbiol Infect 2011, 17:557-565.
10. Clinical and Laboratory Standard Institute (CLSI) Performance standards for antimicrobial susceptibility testing; 20th Informational Supplement (June 2010 Update) 2010, CLSI document M100-S20-U, CLSI, Wayne, PA, USA.
11. McCabe W.R., Jackson G.G. Gram-negative bacteremia I. Etiology and ecology. Arch Intern Med 1962, 110:847-855.
12. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
13. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
14. Pérez-Pérez F.J., Hanson N.D. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002, 40:2153-2162.
15. Oteo J., Cercenado E., Cuevas O., Bautista V., Delgado-Iribarren A., Orden B., et al. AmpC beta-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. Diagn Microbiol Infect Dis 2010, 67:270-276.
16. Dunne E.E.F., Fey P.D., Kludt P., Reporter R., Mostashari F., Shillam P., et al. Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC β-lactamase. JAMA 2000, 284:3151-3156.
17. Navarro F., Perez-Trallero E., Marimon J.M., Aliaga R., Gomariz M., Mirelis B. CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999-December 2000). J Antimicrob Chemother 2001, 48:383-389.
18. Doi Y., Paterson D.L., Egea P., Pascual A., López-Cerero L., Navarro M.D., et al. Extended-spectrum and CMY-type β-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. Clin Microbiol Infect 2010, 16:33-38.
19. Blanc V., Mesa R., Saco M., Lavilla S., Prats G., Miró E., et al. ESBL- and plasmidic class C β-lactamase-producing E. coli strains isolated from poultry, pig and rabbit farms. Vet Microbiol 2006, 118:299-304.
20. Hanson N.D., Moland E.S., Hong S.G., Propst K., Novak D.J., Cavalieri S.J. Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 β-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community. Antimicrob Agents Chemother 2008, 52:3814-3816.
21. Rodríguez-Baño J., Alcalá J.C., Cisneros J.M., Grill F., Oliver A., Horcajada J.P., et al. Community infections caused by extended-spectrum β-lactamase producing-Escherichia coli. Arch Intern Med 2008, 168:1897-1902.
22. Díaz M.A., Hernández-Bello J.R., Rodríguez-Baño J., Martínez-Martínez L., Calvo J., Blanco J., et al. The diversity of Escherichia coli producing extended-spectrum ß-lactamases in Spain: second nationwide study. J Clin Microbiol 2010, 48:2840-2845.
23. Ruiz de Alegría C., Rodríguez-Baño J., Cano M.E., Hernández-Bello J.R., Calvo J., Román E., et al. Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain: microbiological and clinical features. J Clin Microbiol 2011, 49:1134-1136.
24. Rodríguez-Baño J., Picón E., Gijón P., Hernández J.R., Ruíz M., Peña C., et al. Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010, 50:40-48.
25. Rodríguez-Baño J., Picón E., Gijón P., Hernández J.R., Cisneros J.M., Peña C., et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. J Clin Microbiol 2010, 48:1726-1731.